Supplementary Information

Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA

David B. Ascher[1], Jerome Wielens[1,2], Tracy L. Nero[1], Larissa Doughty[1], Craig J. Morton[1] & Michael W. Parker[1,3,*]

[1]ACRF Rational Drug Discovery Centre and Biota Structural Biology Laboratory, St Vincent's Institute of Medical Research, 9 Princes Street, Fitzroy, Victoria 3056, Australia.

[2]Department of Medicine, University of Melbourne, 41 Victoria Parade, Fitzroy, Victoria 3065, Australia.

[3]Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria 3052, Australia.

[*] Correspondence should be addressed M.W.P. (mparker@svi.edu.au)

Professor Michael W. Parker, St Vincent's Institute of Medical Research, 9 Princes Street, Fitzroy, Victoria 3056, Australia. Tel. 0061 3 92882499



Figure S1. 4-12% SDS-PAGE analysis of purified NS5A wild-type constructs. Lane 1 contains protein markers (See-Blue Plus 2, Invitrogen), lane 2 $NS5A^{33-202}$ and lane 3 $NS5A^{26-202}$.